Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset 9)

Trial Profile

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset 9)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin degludec (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms onset9
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 20 Sep 2017 Planned End Date changed from 28 Jan 2019 to 29 Jan 2019.
    • 20 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 28 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top